A Case Report of Targeted Therapy with Anlotinib in a Patient with Advanced Breast Metaplastic Carcinoma

References

• Luini A, Aguilar M, Gatti G, et al. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature. Breast Cancer Res Treat. 2007;101:349–353. doi:10.1007/s10549-006-9301-1
   PubMed Web of Science ®Google Scholar
• Lee H, Jung SY, Ro JY, et al. Metaplastic breast cancer: clinicopathological features and its prognosis. J Clin Pathol. 2012;65(5):441–446. doi:10.1136/jclinpath-2011-200586
   PubMed Web of Science ®Google Scholar
• Syed YY. Anlotinib: first global approval. Drugs. 2018;78(10):1057–1062. doi:10.1007/s40265-018-0939-x
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang QM, Li K, et al. Anlotinib as third-line or further-line treatment in relapsed SCLC: a multicenter, randomized, double-blind Phase 2 trial. IASLC 19th World Conference on Lung Cancer. Toronto: IASLC; 2018. Abstract OA13.03.
   Google Scholar
• Han B, Li K, Wang Q, et al. Third-line treatment: a randomized, double-blind, placebo-controlled Phase III ALTER-0303 study—efficacy and safety of anlotinib treatment in patients with refractory advanced NSCLC. J Clin Oncol. 2017;35:9053. doi:10.1200/JCO.2017.35.15_suppl.9053
   Google Scholar
• Chi Y, Sun Y, Cai J, et al. Phase II study of anlotinib for treatment of advanced soft tissues sarcomas. J Clin Oncol. 2016;34(15 Suppl):11005. doi:10.1200/JCO.2016.34.15_suppl.11005
   Google Scholar
• Chi Y, Yao Y, Wang S, et al. Anlotinib for metastasis soft tissue sarcoma: a randomized, double-blind, placebo-controlled and multi-centered clinical trial. J Clin Oncol. 2018;36(15 Suppl):11503. doi:10.1200/JCO.2018.36.15_suppl.11503
   Google Scholar
• Pezzi CM, Patel-Parekh L, Cole K, et al. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol. 2007;14:166–173. doi:10.1245/s10434-006-9124-7
   PubMed Web of Science ®Google Scholar
• Hu Q, Chen WX, Zhong SL, et al. Current progress in the treatment of metaplastic breast carcinoma. Asian Pac J Cancer Prev. 2013;14(11):6221–6225. doi:10.7314/APJCP.2013.14.11.6221
   PubMedGoogle Scholar
• Lakhani SR, Ellise IO, Schnitt SJ, et al. WHO Classification of Tumours of the Breast. 4th ed. Lyon, France: IARC; 2012.
   Google Scholar
• Wang H, B. G, Shi Q, et al. May metaplastic breast carcinomas be actually basal like carcinoma? Further evidence study with its ultrastructure and survival analysis. Med Oncol. 2011;28(1):42–50. doi:10.1007/s12032-009-9399-1
   PubMed Web of Science ®Google Scholar
• Terando AM, Agnese DM, Holmes DR. Treatment and prognosis of rare breast cancers. Ann Surg Oncol. 2015;22(10):3225–3229. doi:10.1245/s10434-015-4748-0
   PubMed Web of Science ®Google Scholar
• Jiang Y-Z, Liu Y, Xiao Y, et al. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial. Cell Res. 2021;31:178–186. doi:10.1038/s41422-020-0375-9
   PubMed Web of Science ®Google Scholar
• Borresen-Dale AL. TP53 and breast cancer. Hum Mutat. 2003;21:292–300. doi:10.1002/humu.10174
   PubMed Web of Science ®Google Scholar
• Lien HC, Lin CW, Mao TL, et al. Tp53 overexpression and mutation in Metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogeneous sarcomatous components. J Pathol. 2004;204:131–139. doi:10.1002/path.1624
   PubMed Web of Science ®Google Scholar
• Bellino R, Arisio R, D’Addato F, et al. Metaplastic breast carcinoma: pathology and clinical outcome. Anticancer Res. 2003;23:669–673.
   PubMed Web of Science ®Google Scholar
• Said R, Hong DS, Warneke CL, et al. TP53 mutations in advanced cancers: clinical characteristics, outcomes, and correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget. 2013;4:705–714. doi:10.18632/oncotarget.974
   PubMedGoogle Scholar
• Fang S, Cheng W, Zhang M, et al. Association of TP53 mutations with response to anlotinib treatment in advanced non-small cell lung cancer. Onco Targets Ther. 2020;13:6645–6650. doi:10.2147/OTT.S257052
   PubMed Web of Science ®Google Scholar
• Koehler K, Liebner D, Chen JL. TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol. 2016;27(3):539–543. doi:10.1093/annonc/mdv598
   PubMed Web of Science ®Google Scholar
• Wu Y, Huang J, Wang Q, et al. Whole-exome sequencing insights into pulmonary artery sarcoma mimicking pulmonary embolism: a case report and review. Onco Targets Ther. 2019;12:6227–6235. doi:10.2147/OTT.S212416
   PubMed Web of Science ®Google Scholar
• Kataoka Y, Mukohara T, Shimada H, et al. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol. 2010;21(2):255–262. doi:10.1093/annonc/mdp304
   PubMed Web of Science ®Google Scholar
• Das A, Mahapatra S, Bandyopadhyay D, et al. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: a network meta-analysis. Crit Rev Oncol Hematol. 2021;57:103186. doi:10.1016/j.critrevonc.2020.103186
   Google Scholar
• Song F, Hu B, Cheng J-W. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma. Cell Death Dis. 2020;11:573. doi:10.1038/s41419-020-02749-7
   PubMed Web of Science ®Google Scholar
• Liu S, Qin T, Liu Z, et al. Anlotinib alters tumor immune microenvironment by downregulating PD- L1 expression on vascular endothelial cells. Cell Death Dis. 2020;11(5):309. doi:10.1038/s41419-020-2511-3
   PubMed Web of Science ®Google Scholar
• Moulder S, Moroney J, Helgasonn T, et al. Responses to liposomal doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer. J Clin Oncol. 2011;29(19):e572–e575. doi:10.1200/JCO.2010.34.0604
   PubMed Web of Science ®Google Scholar
• Hu N, Si Y, Yue J, et al. Anlotinib has good efficacy and low toxicity: a phase II study of anlotinib in pre-treated HER2 negative metastatic breast cancer. Cancer Biol Med. 2021;18:2095–3941. doi:10.20892/j.issn.2095-3941.2020.0463
   Web of Science ®Google Scholar